Metagenomi Therapeutics, Inc. (MGX)
1.02
+0.02
(+2.00%)
USD |
NASDAQ |
Oct 12, 16:00
1.02
0.00 (0.00%)
After-Hours: 20:00
Metagenomi Therapeutics EPS Diluted (Quarterly) : -0.7298 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.7298 |
| March 31, 2026 | -0.6136 |
| December 31, 2025 | -0.5988 |
| September 30, 2025 | -0.546 |
| June 30, 2025 | -0.5358 |
| March 31, 2025 | -0.6764 |
| December 31, 2024 | -0.6253 |
| September 30, 2024 | -0.5106 |
| Date | Value |
|---|---|
| June 30, 2024 | -0.2867 |
| March 31, 2024 | -1.190 |
| December 31, 2023 | -0.5149 |
| September 30, 2023 | -0.5289 |
| June 30, 2023 | -0.3472 |
| March 31, 2023 | -4.739 |
| December 31, 2022 | -0.3903 |
| September 30, 2022 | -0.277 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Oncolytics Biotech, Inc. | -0.0788 |
| Sangamo Therapeutics, Inc. | -0.0796 |
| Sarepta Therapeutics, Inc. | -0.0464 |
| Anixa Biosciences, Inc. | -0.0762 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -27.48M |
| Revenue (Quarterly) | -0.257M |
| Total Expenses (Quarterly) | 27.22M |
| Enterprise Value | -44.41M |
| Earnings Yield | -243.9% |
| Normalized Earnings Yield | -243.94 |